Ct Healthcare Trust Plc — Result of Quarterly Tender

CT Healthcare Trust will repurchase 3.89 million shares after strong shareholder approval.

What the company is saying

CT Healthcare Trust plc is reporting the outcome of its quarterly tender offer, which allowed shareholders to tender up to 15% of the company’s issued shares (excluding treasury shares). The company highlights that 3,885,283 shares, representing 8.37% of the 46,432,942 shares in issue, were validly tendered and will be repurchased. The announcement emphasizes that all resolutions related to the tender offer were passed with overwhelming support at the general meeting, with the ordinary resolution receiving 99.39% and the special resolution 99.42% of votes in favour. The company frames the process as transparent and procedural, specifying that the purchase price will be set at the prevailing Net Asset Value per share as of 1 September 2026, less expenses, with the final price to be announced later. The tone is factual and administrative, focusing on process completion and shareholder approval rather than future benefits or strategic implications. No explanation is provided for why the number of shares tendered was below the 15% maximum, and there is no commentary on financial performance or outlook.

What the data suggests

The data confirms that 3,885,283 shares, or 8.37% of shares in issue, were validly tendered and will be repurchased, well below the maximum 6,998,907 shares (15%) allowed under the offer. The total shares in issue, excluding treasury, stand at 46,432,942. Shareholder support for the resolutions was nearly unanimous, with 14,780,127 votes (99.39%) for the ordinary resolution and 14,784,715 votes (99.42%) for the special resolution, and minimal opposition (90,352 and 85,764 votes against, respectively). The process for allocating shares among tendering shareholders followed the published rules, but no breakdown of Basic Entitlement or Excess Applications is provided. The final purchase price per share is not disclosed, only that it will be based on the NAV as of 1 September 2026 less expenses. No financial performance data, NAV per share, or impact on company value is included. The announcement is thorough on procedural outcomes but omits any discussion of financial trajectory or rationale for the tender offer.

Analysis

The announcement is a factual disclosure of the results of a quarterly tender offer, including the number of shares tendered, percentages, and voting outcomes. The language is procedural and does not contain promotional or exaggerated claims. The only forward-looking element is the pending disclosure of the final Tender Price, which is a routine administrative step and not an aspirational projection. There is no discussion of future benefits, synergies, or financial impact beyond the immediate mechanics of the share repurchase. No large capital outlay or long-term benefit is described, and the process is already underway with results disclosed. The gap between narrative and evidence is negligible, as all key claims are supported by specific numbers and outcomes.

Risk flags

• ●The announcement does not disclose the actual Net Asset Value per share or the final Tender Price, limiting investors’ ability to assess the financial impact of the buyback until that information is released.
• ●There is no commentary on the rationale for the tender offer or its expected effect on shareholder value, leaving the strategic motivation and potential consequences unaddressed.
• ●The number of shares tendered was significantly below the maximum allowed, which could indicate limited shareholder appetite for liquidity or a lack of confidence in the offer terms, but no explanation is provided.

Bottom line

CT Healthcare Trust plc will repurchase 3.89 million shares, or 8.37% of its issued share capital, following strong shareholder approval at the general meeting. The process was executed according to plan, but the final purchase price per share remains undisclosed and is necessary to assess the financial impact of the buyback. The company provides no commentary on why the tender uptake was below the 15% cap or how the buyback fits into broader capital management strategy. Investors should watch for the final Tender Price announcement and any subsequent commentary on the effect of the repurchase on NAV per share and long-term value. The main takeaway is that the tender offer was completed with high procedural transparency but limited financial disclosure.

Announcement summary

(LSE:CTHT) CT Healthcare Trust plc announced the results of its quarterly tender offer for up to 15 per cent. of the Company's issued Shares (excluding any Shares held in treasury). 3,885,283 Shares were validly tendered, equal to approximately 8.37 per cent. of the 46,432,942 Shares in issue (excluding any Shares held in treasury). The maximum number of Shares to be acquired under the Tender Offer is 6,998,907 Shares, representing 15 per cent. of the Shares in issue as at 5 August 2026. The Company will purchase in aggregate 3,885,283 Shares under the Tender Offer. The price at which tendered Shares will be purchased will be equal to the prevailing Net Asset Value per Share as at the Calculation Date of 1 September 2026 less the Tender Offer Expenses per Share. At the General Meeting held on 2 September 2026, each of the resolutions proposed was duly passed on a poll. The Ordinary Resolution to approve the sale of Shares under the Matching Facility at a price less than prevailing NAV per Share received 14,780,127 votes in favour (99.39%) and 90,352 votes against (0.61%), with 81,931 votes withheld. The Special Resolution to approve the repurchase of Shares pursuant to the Tender Offer received 14,784,715 votes in favour (99.42%) and 85,764 votes against (0.58%), with 81,931 votes withheld.

Disagree with this article?